Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | GAK | O14976 | 3/20 | 0.42 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | STK16 | O75716 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27947745 | 0.81 | MTNR1B (0.50) | PDPK1PDE10AMAPTALDH1A1RAB9A | |
| SCHEMBL5221215 | 0.81 | PDE10A (0.48) | PDPK1PDE10AMAPTALDH1A1NPC1 | |
| SCHEMBL26317670 | 0.79 | PDGFRA (0.47) | EGFRPDPK1PDE10AALDH1A1KDM4E | |
| SCHEMBL2203334 | 0.79 | PDPK1 (0.45) | PDPK1PDE10AMAPTALDH1A1NPC1 | |
| SCHEMBL2815588 | 0.79 | PDPK1 (0.45) | EGFRPDPK1PDE10AALDH1A1KDM4E | |
| SCHEMBL11154928 | 0.79 | DOT1L (0.46) | PDPK1PDE10AALDH1A1NPC1KDM4E | |
| SCHEMBL21849067 | 0.77 | FGFR2 (0.45) | PDPK1PDE10AALDH1A1KDM4EPDE3B | |
| SCHEMBL2204825 | 0.77 | PDPK1 (0.43) | EGFRPDPK1PDE10AMAPTALDH1A1 | |
| SCHEMBL23674641 | 0.77 | CYP1A2 (0.39) | MAPTALDH1A1NPSR1PDE3BPDE3A | |
| SCHEMBL23248035 | 0.76 | ABCB1 (0.44) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2025-08-14 | — | — | US | disclosed |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2024-09-24 | — | — | US | disclosed |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2023-12-07 | — | — | US | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2021-07-29 | — | — | US | disclosed |
| CN-107847765-B | 1, 4-substituted piperidine derivatives | 89生物有限公司 | 2021-05-04 | — | — | CN | disclosed |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2020-12-01 | — | — | US | disclosed |
| EP-3310441-B1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-07-29 | — | — | EP | disclosed |
| US-20190152913-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2019-05-23 | — | — | US | disclosed |
| US-10221135-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2019-03-05 | — | — | US | disclosed |
| EP-3310441-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2016-12-22 | — | — | US | disclosed |
| WO-2016205633-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| EP-1868998-B1 | NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | VFP THERAPIES (FR) | 2016-05-25 | — | — | EP | disclosed |
| US-7977354-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | INSA ROUEN (FR) | 2011-07-12 | — | — | US | disclosed |
| US-20090062279-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | INSA ROUEN (FR) | 2009-03-05 | — | — | US | disclosed |
| EP-1868998-A2 | NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | Insa Rouen (FR) | 2007-12-26 | — | — | EP | disclosed |
| EP-1731507-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | Institut National des Sciences Appliquees de Rouen (INSA) (FR) | 2006-12-13 | — | — | EP | disclosed |
| WO-2006103120-A2 | NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | INSA ROUEN (FR) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | EGFR 4101/4885PDPK1 543/4885PDE10A 1312/4885 |
| US-20190152913-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | EGFR 4101/4885PDPK1 543/4885PDE10A 1312/4885 |
| US-20090062279-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | NLN, SNCA, APP | EGFR 3661/4885PDPK1 2848/4885PDE10A 991/4885 |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | EGFR 4101/4885PDPK1 543/4885PDE10A 1312/4885 |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | EGFR 4101/4885PDPK1 543/4885PDE10A 1312/4885 |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | EGFR 4101/4885PDPK1 543/4885PDE10A 1312/4885 |
| US-10221135-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | EGFR 4101/4885PDPK1 543/4885PDE10A 1312/4885 |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | EGFR 4101/4885PDPK1 543/4885PDE10A 1312/4885 |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | EGFR 4101/4885PDPK1 543/4885PDE10A 1312/4885 |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | EGFR 4101/4885PDPK1 543/4885PDE10A 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.